|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function.
|
28452372 |
2017 |
|
Creatinine measurement, serum (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function.
|
28452372 |
2017 |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Oct-2 gene was expressed in 82% of pre-B ALL and all B-CLL samples.
|
10905058 |
2000 |
|
Precursor B-cell lymphoblastic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Oct-2 gene was expressed in 82% of pre-B ALL and all B-CLL samples.
|
10905058 |
2000 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Oct-2 gene was expressed in 82% of pre-B ALL and all B-CLL samples.
|
10905058 |
2000 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Oct-2 gene was expressed in 82% of pre-B ALL and all B-CLL samples.
|
10905058 |
2000 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
OCT-2 immunostaining was primarily restricted in normal lymphoid tissue to B cells, and was absent from most T-cell neoplasms.
|
12598320 |
2003 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
SLC22A2 and SLC22A3, two genes downstream of IGF2R that are imprinted in the mouse, showed no T1D association.
|
15531531 |
2004 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Oct-2, therefore, acts as a cell survival factor in t(14;18) lymphoma cells by directly activating the antiapoptotic gene bcl-2.
|
16186795 |
2006 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oct-2, therefore, acts as a cell survival factor in t(14;18) lymphoma cells by directly activating the antiapoptotic gene bcl-2.
|
16186795 |
2006 |
|
Childhood Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oct-2, therefore, acts as a cell survival factor in t(14;18) lymphoma cells by directly activating the antiapoptotic gene bcl-2.
|
16186795 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Oct2 was expressed strongly in 12 of 16 AML cases with t(8;21) and 19 of 46 without t(8;21).
|
16891199 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
OCT-2 may act as a cell survival factor in AML by mediating expression of downstream targets, such as BCL-2.
|
20141429 |
2010 |
|
Multiple Myeloma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Oct2 should be explored as a potential selective therapeutic target in myeloma.
|
21438833 |
2011 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Organic cation transporter 2 (OCT2), which is a cisplatin uptake transporter expressed on renal tubules and cochlear hair cells but not on osteosarcoma cells, mediates cisplatin uptake.
|
29445029 |
2018 |
|
Osteosarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Organic cation transporter 2 (OCT2), which is a cisplatin uptake transporter expressed on renal tubules and cochlear hair cells but not on osteosarcoma cells, mediates cisplatin uptake.
|
29445029 |
2018 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Organic cation transporter 2 (OCT2), which is a cisplatin uptake transporter expressed on renal tubules and cochlear hair cells but not on osteosarcoma cells, mediates cisplatin uptake.
|
29445029 |
2018 |
|
Psychiatric symptom
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV.
|
30561642 |
2019 |
|
Anxiety
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
SLC22A2 CA genotype was independently associated with an abnormal GSI [adjusted OR (aOR) 2.43; P = 0.072], anxiety (aOR 2.61; P = 0.044), hostility (aOR 3.76; P = 0.012) and with moderate to severe headache (aOR 5.55; P = 0.037), and dolutegravir Ctrough was associated with hostility (fourth versus first quartile aOR 6.70; P = 0.007) and psychoticism (fourth versus first quartile aOR 19.01; P = 0.008).
|
30561642 |
2019 |
|
Anxiety Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
SLC22A2 CA genotype was independently associated with an abnormal GSI [adjusted OR (aOR) 2.43; P = 0.072], anxiety (aOR 2.61; P = 0.044), hostility (aOR 3.76; P = 0.012) and with moderate to severe headache (aOR 5.55; P = 0.037), and dolutegravir Ctrough was associated with hostility (fourth versus first quartile aOR 6.70; P = 0.007) and psychoticism (fourth versus first quartile aOR 19.01; P = 0.008).
|
30561642 |
2019 |
|
Psychoticism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
SLC22A2 CA genotype was independently associated with an abnormal GSI [adjusted OR (aOR) 2.43; P = 0.072], anxiety (aOR 2.61; P = 0.044), hostility (aOR 3.76; P = 0.012) and with moderate to severe headache (aOR 5.55; P = 0.037), and dolutegravir Ctrough was associated with hostility (fourth versus first quartile aOR 6.70; P = 0.007) and psychoticism (fourth versus first quartile aOR 19.01; P = 0.008).
|
30561642 |
2019 |
|
Kidney Failure, Chronic
|
0.300 |
GeneticVariation
|
disease |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Lipoprotein (a) measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms.
|
28512139 |
2017 |
|
Hodgkin Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Absence of Oct-2 and Bob-1 protein expression in primary H-RS cells was demonstrated by performing immunohistochemistry in 20 cases of classical Hodgkin's disease.
|
11280769 |
2001 |